Kokuma develops patented active ingredients that inhibit melanogenesis by up to 86%, effectively reducing dark spots and promoting a more uniform skin tone. Their technology leverages AI-driven research to enhance melanin synthesis, providing consumers with the ability to naturally influence their skin pigmentation.
Funding
Funding not disclosed
Founders
Product
Problem
Current depigmentation solutions often rely on tyrosinase inhibitors, which may lack optimal efficacy and raise safety concerns. Existing methods for influencing skin pigmentation may not fully leverage natural physiological pathways.
Solution
Kokuma develops active ingredients that modulate melanin production through natural physiological pathways. Their lead ingredients, TONASULIKE-D and TONASULIKE-P, offer cosmetic brands novel approaches to skin tone enhancement. TONASULIKE-D inhibits melanogenesis, reducing dark spots and promoting even skin tone, while TONASULIKE-P enhances melanin synthesis for a radiant complexion or UV-free tan. These ingredients are supported by in-vitro and ex-vivo studies demonstrating significant effects on melanin production and tyrosinase expression. Kokuma utilizes AI-driven research to identify and optimize these active ingredients, ensuring efficacy and safety.
Target Audience
Kokuma's primary customers are cosmetic brands and formulators seeking innovative and effective active ingredients for skin tone enhancement products.
Features
- TONASULIKE-D: Demonstrated up to 86% inhibition of melanogenesis in-vitro.
- TONASULIKE-D: Shown to decrease tyrosinase expression by 2.4-fold in human skin explants under UV exposure.
- TONASULIKE-P: Clinically validated to balance skin pigmentation by enhancing melanin synthesis.
- TONASULIKE-P: Achieved a twofold increase in melanin content in skin explants in a sunless environment compared to UV-exposed explants.
- AI-driven ingredient selection through predictive testing and data modeling.
- Ingredients inspired by nature and physiological processes.